Eli Lilly Again Boosts FY24 Outlook - Update
2024-08-01
3318
(fxcue news) - While reporting financial results for the second quarter on Thursday, drugmaker Eli Lilly and Co. (LLY) raised its earnings, adjusted earnings and revenue guidance for the full-year 2024, primarily driven by the strong performance of Mounjaro and Zepbound, as well as the company's non-incretin medicines.
For fiscal 2024, Eli Lilly now projects earnings in a range of $15.10 to $15.60 per share and adjusted earnings in a range of $16.10 to $16.60 per share on revenues between $45.4 billion and $46.6 billion.
Previously, the company expected earnings in the range of $13.05 to $13.55 per share and adjusted earnings in the range of $13.50 to $14.00 per share on revenues between $42.4 billion and $43.6 billion.
On average, analysts polled by Thomson Reuters expect the company to report earnings of $13.76 per share on revenues of $43.01 billion for the year. Analysts' estimates typically exclude special items.
For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com
Sign In via X
Google
Sign In via Google
This page link：http://www.fxcue.com/44721.html
Tips：This page came from Internet, which is not standing for FXCUE opinions of this website.
Statement：Contact us if the content violates the law or your rights
Tips：This page came from Internet, which is not standing for FXCUE opinions of this website.
Statement：Contact us if the content violates the law or your rights